Bendit is developing the next generation of steerable microcatheters, free from guidewires and pulling wires, making seamless navigation into every blood vessel possible.

Beyeonics Surgical is a medical technology company developing surgeon-centered visualization solutions

EPF is developing a novel cardiac ablation catheter for pulmonary vein isolation and atrial fibrillation treatment. The technology under clinical investigation is a unique single shot ablation catheter with anchoring and stabilization features, that aims to improve both the effectiveness of the clinical outcome and the ease of use for the EP.

EP Solutions SA has developed a novel non-invasive cardiac mapping approach. The technology allows to plan and optimize cardiac resynchronization therapy. It is expected to lead to better outcomes and lower costs for managing heart failure patients.

Inotec is a company active in wound healing and focused on diabetic foot ulcers. It commercializes Natrox ® Oxygen Wound Therapy, a therapeutic wearable device that delivers 98% pure humified oxygen to stimulate healing in wounds. Natrox ® is FDA approved and CE marked.

Nitinotes is developing EndoZip™, fully automated operator-independent gastroscopic suturing device for easier and safer volume restriction and motility impairment procedures targeting weight loss for obese patients.

Nocturnal Labs is an operational industrial holding that invests in companies developing disruptive healthcare products, services and technologies.

SentiAR’s is transforming the experience for both patient and clinician in interventional procedures with a 3D augmented reality platform featuring real-time holographic visualization of the patient’s actual anatomy.

The visualization is fully controllable “hands-free” by the clinician, providing an ergonomic breakthrough for the treatment and analysis of cardiac arrhythmias within an interventional catheter lab environment.

Sonivie is developing Tivus™, contactless ultrasound catheter for pulmonary artery denervation for a safe and effective treatment of pulmonary hypertension. TIVUS selectively damages nerves associated with disease activity without touching the vessel walls or damaging the adjacent tissues. This treatment aims at significantly slow the disease progression.

Valcare has developed a portfolio of transcatheter technologies to treat mitral and tricuspid regurgitation. The system allows for different and personalised therapeutical approaches, is based on a transcatheter valve ring for annuloplasty, whose ongoing clinical trials are demonstrating superior clinical outcome and ease of procedure, and on a transcatheter valve replacement prosthesis, and can be delivered through both transapical and transeptal approaches.